Company intelligence / Profile preview

Trethera

Santa Monica, California, USAtrethera.com ↗

Ownership: Private
Employees: ~7
Development stage: Phase 1

Overview

TRE‑515, an orally delivered first-in-class inhibitor of deoxycytidine kinase, has received FDA Orphan Drug designation for two diseases. It has demonstrated tolerability and potential efficacy in early clinical development targeting both cancer and autoimmune disease by exploiting metabolic vulnerabilities unique to diseased cells. The company positions TRE‑515 as potentially safer with fewer side effects compared to traditional therapies.

Therapeutic areas: OncologyImmunologyRare Diseases
Modalities: Small molecules (notably oral small molecule inhibitors)
Industry: Biotech

Drug pipeline

1 asset

TRE-515

Partnerships

Collaborations with key academic groups including UCLA; pharmaceutical partnerships mentioned but not named specifically

Beyond the preview

Go deeper on Trethera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trethera.

Explore the full profile